SOUTH SAN FRANCISCO, Calif., Nov 20, 2007 (PrimeNewswire via COMTEX News Network) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the dosing of the first two patients in a Phase 2 clinical trial of Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) for the treatment of metastatic malignant uveal melanoma.
